
We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: bit.ly/4jrAErw
Lightstone Ventures
47 posts

@LightstoneVC
Dedicated to empowering entrepreneurs with the resources and guidance needed to bring their innovative therapeutics to patients.

We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: bit.ly/4jrAErw

We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. prnewswire.com/news-releases/…


We’re pleased to announce the addition of $47M to our Series B-1 Extension to advance our CVN424 therapy for the treatment of PD into a Phase 3 clinical trial and to support our robust pipeline of CNS treatments. Read more here: brnw.ch/21wJaqe

Relievant is now Boston Scientific. Follow @bostonsci to stay up to date as we advance pain management solutions as part of Neuromodulation at Boston Scientific. Learn more here: bit.ly/3sNpJTH




ALX Oncology today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial: bit.ly/3Q1LRTl

We’re pleased to announce that the first subject has been dosed in our Phase 1 clinical study evaluating CVN293, a selective inhibitor designed to modulate neuroinflammation for the treatment of ALS and Alzheimer’s disease. Read the release to learn more: brnw.ch/21wCJ2h


We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more: bit.ly/47VJ0Ca

We’re thrilled to announce that @FierceBiotech has named us a #Fierce15 biotech company of 2023. It is an honor to be acknowledged within this outstanding array of industry experts, and a testament to the groundbreaking work we are doing at Cerevance: brnw.ch/21wC3bg

We are in the US! Another great milestone for the FIRE1 team in its mission to help people with heart failure live their normal lives, thanks to all our docs across the US for making this happen and our National PI @NirUrielMD dicardiology.com/content/first-…

We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics ! tagworkspharma.com/tagworks-pharm…

A new study in Interventional Pain Medicine details 3-year pooled outcomes from the #Intracept Procedure that demonstrate long-term pain relief and reduced opioid use in chronic #vertebrogenic low back pain patients. Read our press release to learn more: bit.ly/3oYzsoy
